Nevro Stock News

REDWOOD CITY, Calif., Nov. 30, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced two poster presentations at the International Society for

It doesn't take a lot to own a piece of these rapidly growing healthcare businesses.

The stock price of Nevro, a medical devices company, has seen a large 22% fall in a month. This can largely be attributed to the outcome of a lawsuit against Nevro for patent infringement, with the ju

During the last session, Nevro Corp. (NYSE:NVRO)s traded shares were 0.82 million, with the beta value of the company hitting 1.00. At the end of the trading day, the stocks price was $92.59, reflecting an intraday gain of 5.25% or $4.62. The 52-week high for the NVRO share is $188.14, that puts it down -103.2 Nevro Corp. (NYSE: NVRO): Can A Stock Thats Down -46.51% YTD Still Be Considered In Loss Territory? Read More »

Several brokerages have updated their recommendations and price targets on shares of Nevro (NYSE: NVRO) in the last few weeks: 11/19/2021 Nevro had its buy rating reaffirmed by analysts at SVB Leerink LLC. They now have a $128.00 price target on the stock. 11/9/2021 Nevro had its price target lowered by analysts at []

SVB Leerink reiterated their buy rating on shares of Nevro (NYSE:NVRO) in a report published on Friday morning, TipRanks reports. SVB Leerink currently has a $128.00 target price on the medical equipment providers stock. NVRO has been the subject of a number of other reports. Truist Financial downgraded Nevro to a hold rating and set []

Analysts forecast that Nevro Corp. (NYSE:NVRO) will post $96.54 million in sales for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Nevros earnings. The lowest sales estimate is $95.88 million and the highest is $97.47 million. Nevro reported sales of $109.73 million during the same quarter last year, which would []

Nevro Corp. (NYSE:NVRO) price on Friday, November 19, fall -1.64% below its previous days close as a downside momentum from buyers pushed the stocks value to $86.83. A look at the stocks price movement, the close in the last trading session was $88.28, moving within a range at $86.04 and $90.99. The beta value (5-Year Nevro Corp.: When The Timing Is Right, Sit Tight Read More »

DUBLIN, Nov. 18, 2021 /PRNewswire/ -- The "Pain Management Devices Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com''s offering. The global pain management devices market is expected to grow at a compound annual growth rate of 11.04% over the forecast

AQR Capital Management LLC lessened its stake in shares of Nevro Corp. (NYSE:NVRO) by 17.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 7,653 shares of the medical equipment providers stock after selling 1,666 shares during the quarter. AQR Capital Management LLCs holdings in Nevro were worth $1,269,000 as of its most recent []

Brokerages forecast that Nevro Corp. (NYSE:NVRO) will report earnings of ($0.85) per share for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Nevros earnings, with estimates ranging from ($0.93) to ($0.74). Nevro reported earnings of ($0.21) per share during the same quarter last year, which would indicate a negative year-over-year []

Nevro (NVRO) reported wider-than-expected loss during the third quarter with a year-over-year decline in revenues across U.S. and international businesses.

Nevro Corp. (NVRO) CEO Keith Grossman on Q3 2021 Results - Earnings Call Transcript

Nevro (NVRO) delivered earnings and revenue surprises of -1.16% and 2.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Nevro (NYSE:NVRO) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement.